A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 56, Issue 10, 2015, Pages 2826-2833

  Kipps, Thomas J ^a   Eradat, Herbert ^b   Grosicki, Sebastian ^c   Catalano, John ^d   Cosolo, Walter ^e   Dyagil, Iryna S ^f   Yalamanchili, Sreeni ^g   Chai, Akiko ^g   Sahasranaman, Srikumar ^g   Punnoose, Elizabeth ^g   Hurst, Deborah ^g   Pylypenko, Halyna ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Hematology   (Poland)

^d MONASH UNIVERSITY   (Australia)

^e John Fawkner Cancer Trial Centre   (Australia)

^f INSTITUTE OF HYDROBIOLOGY   (Ukraine)

^g GENENTECH INC   (United States)

^h Regional Oncological Center   (Ukraine)

Author keywords

ABT 263; B cell; BCL2; BH3; chronic lymphocytic leukemia; clinical trial; navitoclax; rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; FLUDARABINE; NAVITOCLAX; RITUXIMAB; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; PROTEIN BCL 2; SULFONAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; INFUSION RELATED REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SERUM SICKNESS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RITUXIMAB; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84947566364     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1030638     Document Type: Article

References (29)

1. Barille-Nion S, Bah N, Vequaud E, et al. Regulation of cancer cell survival by BCL2 family members upon prolonged mitotic arrest: opportunities for anticancer therapy. Anticancer Res 2012;32: 4225-4233.
2. Fegan C, Pepper C. Apoptosis deregulation in CLL. Adv Exp Med Biol 2013;792:151-171.
3. Billard C. BH3 mimetics: status of the field and new developments. Mol Cancer Ther 2013;12:1691-1700.
4. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-681.
5. Del Gaizo Moore V, Brown JR, Certo M, et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007;117:112-121.
6. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-3428.
7. Tedeschi A, Vismara E, Ricci F, et al. The spectrum of use of rituximab in chronic lymphocytic leukemia. Oncol Targets Ther 2010;3:227-246.
8. Ackler S, Mitten MJ, Foster K, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 2010;66:869-880.
9. Ackler S, Mitten MJ, Chen J, et al. Navitoclax (ABT-263) and bendamustine ?/-rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol 2012;167:881-891.
10. Al-Harbi S, Hill BT, Mazumder S, et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 2011;118:3579-3590.
11. Merino D, Khaw SL, Glaser SP, et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012;119:5807-5816.
12. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488-496.
13. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
15. Kile BT. The role of apoptosis in megakaryocytes and platelets. Br J Haematol 2014;165:217-226.
16. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
17. Binet JL, Caligaris-Cappio F, Catovsky D, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006;107:859-861.
18. Greipp PT, Smoley SA, Viswanatha DS, et al. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13. 1 and 11q22. 3 have a very poor prognosis. Br J Haematol 2013;163:326-333.
19. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
20. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11: 1149-1159.
21. National Cancer Institute, National Institutes for Health. Common Terminology Criteria for Adverse Events (CTCAE). v. 4. 03. 14 June 2010. Available from: http://evs. nci. nih. gov/ftp1/CTCAE/CTCAE-4. 03-2010-06-14-QuickReference-5x7. pdf
22. Choo EF, Boggs J, Zhu C, et al. The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199. Drug Metab Dispos 2014;42: 207-212.
23. Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDECC2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 2000;22:295-301.
24. Cook JR, Craig FE, Swerdlow SH. bcl-2 expression by multicolor flow cytometric analysis assists in the diagnosis of follicular lymphoma in lymph node and bone marrow. Am J Clin Pathol 2003;119:145-151.
25. Rich JT, Neely JG, Paniello RC, et al. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg 2010;143:331-336.
26. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-208.
27. Li J, Zhi J, Wenger M, et al. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol 2012;52:1918-1926.
28. Kodama T, Takehara T, Hikita H, et al. Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology 2010;138:2487-2498, 2498. e1-7.
29. Schoenwaelder SM, Jarman KE, Gardiner EE, et al. BclxL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011;118: 1663-1674.